University Hospitals Partners with Luna to Expand Access to In-home, In-person, Outpatient PT Services

University Hospitals (UH), one of the nation’s leading healthcare systems based in Cleveland, Ohio, has joined forces with Luna, the leading provider of in-home, in-person outpatient physical therapy, to expand access to services.

Patients seeking care will have safe, high-quality physical therapy conveniently delivered to them at home. The service, a first for Cleveland, will be available to all residents without a referral required to start.

The new collaboration, known as University Hospitals Physical Therapy At Home, will start taking appointments in Q4, 2023.

According to a national report from Luna, health systems lose $3.1 billion revenue from physical therapy referral leakage, equating to an average loss of $2,500 per patient.

Unlike remote or virtual care, Luna’s licensed physical therapists provide 1:1 hands-on care in the convenience of the patient’s home. With Luna, patients can request in-home physical therapy via the Luna app. A licensed physical therapist is then scheduled to arrive at the patient’s home for a 45-55 minute appointment, and continues the in-person treatment at home for the duration of the care plan.

The University Hospitals Physical Therapy At Home service will be covered by most major insurances with the same co-pay cost as facility-based care.

“By partnering with Luna, we are reducing barriers to access high quality, convenient physical therapy direct to a patient’s home,” said Bill Benoit, MOT, MBA, FACHE, Chief Operating Officer, UH South Market. “Patients appreciate flexibility when it comes to scheduling appointments, and we look forward to meeting patients where they are in their care journey through this innovative collaboration.”

“Health systems are turning to Luna to expand access to physical therapy beyond the geographic limits of their facilities,” said Palak Shah, Co-Founder and Head of Clinical Operations at Luna. “By partnering with Luna, health systems enable their patients to complete treatment at a convenient place and time, which leads to improved outcomes and patient satisfaction. We’re excited to be partnering with UH to roll out in-home, in-person outpatient physical therapy to their community.”

As part of the partnership, UH patients will be matched with a local Luna therapist at the time and location of their choosing, based on specialty, geography, schedule, and other factors. For consistency of care, the same therapist will treat patients for the entirety of the treatment plan, and patients and therapists will be able to communicate with each other and discuss care needs between visits.

Leading health systems such as Providence, Emory Healthcare, Intermountain Healthcare, and Scripps Health have partnered with Luna to offer outpatient physical therapy in the convenience of a patient’s home.

Luna currently operates across 56 markets in 28 states, has treated almost 50,000 patients in their homes, and performs an in-person visit every 25 seconds in the home.

According to a McKinsey report, up to $265 billion worth of care services, representing up to 25 percent of the total cost of care, is expected to shift to the home by 2025.

SourceLuna
Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy